Skip to main content

Dr. Maky Zanganeh

Equibles does not estimate personal net worth.

Get an email with a short summary when Summit Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.

Get SMMT alerts

About Dr. Maky Zanganeh

Dr. Maky Zanganeh is recorded as CEO at Summit Therapeutics Inc. (SMMT). Summit Therapeutics Inc. reported in an 8-K filed July 26, 2022 that Dr. Maky Zanganeh was appointed Co-Chief Executive Officer and President, effective July 25, 2022. Dr. Maky Zanganeh has spoken on 3 earnings calls across 1 company, most recently for Summit Therapeutics Inc. on February 23, 2026. Summit Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Summit Therapeutics Inc. includes Glyn Edwards (CEO), Mahkam Zanganeh (CEO, COO and Board Member), Robert Duggan (CEO and Board Member) and 7 others.

“Effective July 25, 2022, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) appointed Dr. Maky Zanganeh to serve as Co-Chief Executive Officer and President of the Company.”
Summit Therapeutics Inc. Form 8-K, filed July 26, 2022 · Read the filing

Dr. Maky Zanganeh on recent calls

“I'd encourage you to use the webcast link to see the slides being presented this afternoon that will accompany our comments following comments from our team we will take questions and with that i'd like to hand it over to mickey thank you dave good afternoon everyone and thank you for joining us today i'm very proud…”
CEO, Summit Therapeutics Inc. Q4 FY2025 Earnings Call ·
“As Bob said, I remain incredibly enthusiastic about the future of Summit and the possibilities of what can be accomplished with our lead candidate, Ibanezimab, especially as we approach our first global phase three readout and begin to grow our commercial team.”
CEO, Summit Therapeutics Inc. Q1 FY2025 Earnings Call ·
“As Bob said, I remain incredibly enthusiastic about the future of Summit and the possibilities of what can be accomplished with our lead candidate, Ivanissimab.”
CEO, Summit Therapeutics Inc. Q4 FY2024 Earnings Call ·

Affiliation history

Company network

Leadership on record at Summit Therapeutics Inc.

Recent activity